Technical Analysis for VCNX - Vaccinex, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical VCNX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -2.89% | |
| Oversold Stochastic | Weakness | -2.89% | |
| Stochastic Buy Signal | Bullish | -6.37% | |
| Narrow Range Bar | Range Contraction | -6.37% | |
| Wide Bands | Range Expansion | -6.37% | |
| Oversold Stochastic | Weakness | -6.37% | |
| Narrow Range Bar | Range Contraction | -7.48% | |
| Inside Day | Range Contraction | -7.48% | |
| Wide Bands | Range Expansion | -7.48% | |
| Oversold Stochastic | Weakness | -7.48% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Lower Bollinger Band Support | about 2 hours ago |
| Down 5% | about 2 hours ago |
| Down 3% | about 2 hours ago |
| Down 2 % | about 2 hours ago |
Get a Trading Sidekick!
- Earnings date: 09/27/2019
Vaccinex, Inc. Description
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Immunology Clinical Development Immune System Antibodies Monoclonal Antibodies Small Cell Lung Cancer Antibody Melanoma Non Small Cell Lung Cancer Multiple Sclerosis Degenerative Disease Degenerative Diseases Sarcoma Serious Diseases Immune Disorders Neurodegenerative Diseases Autoimmune Disorders Treatment Of Non Small Cell Lung Cancer Nsclc Human Monoclonal Antibodies Osteosarcoma Tolerx Treatment Of Multiple Sclerosis Seth Lederman Vaccinia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.56 |
| 52 Week Low | 1.63 |
| Average Volume | 6,729,277 |
| 200-Day Moving Average | 3.39 |
| 50-Day Moving Average | 3.25 |
| 20-Day Moving Average | 2.96 |
| 10-Day Moving Average | 2.71 |
| Average True Range | 0.27 |
| ADX | 20.66 |
| +DI | 21.05 |
| -DI | 27.30 |
| Chandelier Exit (Long, 3 ATRs ) | 3.33 |
| Chandelier Exit (Short, 3 ATRs ) | 3.20 |
| Upper Bollinger Band | 3.58 |
| Lower Bollinger Band | 2.33 |
| Percent B (%b) | 0.07 |
| BandWidth | 42.10 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.0604 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.68 | ||||
| Resistance 3 (R3) | 2.69 | 2.62 | 2.63 | ||
| Resistance 2 (R2) | 2.62 | 2.56 | 2.61 | 2.62 | |
| Resistance 1 (R1) | 2.52 | 2.51 | 2.49 | 2.51 | 2.60 |
| Pivot Point | 2.45 | 2.45 | 2.43 | 2.44 | 2.45 |
| Support 1 (S1) | 2.35 | 2.39 | 2.32 | 2.34 | 2.24 |
| Support 2 (S2) | 2.28 | 2.34 | 2.27 | 2.22 | |
| Support 3 (S3) | 2.18 | 2.28 | 2.21 | ||
| Support 4 (S4) | 2.17 |
